231 related articles for article (PubMed ID: 18769124)
41. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
Roforth MM; Tan C
Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
[TBL] [Abstract][Full Text] [Related]
42. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression.
Aird KM; Ding X; Baras A; Wei J; Morse MA; Clay T; Lyerly HK; Devi GR
Mol Cancer Ther; 2008 Jan; 7(1):38-47. PubMed ID: 18202008
[TBL] [Abstract][Full Text] [Related]
43. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
44. Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2
D'Alesio C; Bellese G; Gagliani MC; Aiello C; Grasselli E; Marcocci G; Bisio A; Tavella S; Daniele T; Cortese K; Castagnola P
J Exp Clin Cancer Res; 2017 Nov; 36(1):154. PubMed ID: 29100552
[TBL] [Abstract][Full Text] [Related]
45. [Management of metastatic HER2-positive breast cancer: present and future].
Guiu S; Coudert B; Favier L; Arnould L; Fumoleau P
Bull Cancer; 2010 Mar; 97(3):365-83. PubMed ID: 20176546
[TBL] [Abstract][Full Text] [Related]
46. Tuning polypeptide-based micellar carrier for efficient combination therapy of ErbB2-positive breast cancer.
Soni KS; Lei F; Desale SS; Marky LA; Cohen SM; Bronich TK
J Control Release; 2017 Oct; 264():276-287. PubMed ID: 28870832
[TBL] [Abstract][Full Text] [Related]
47. Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines.
Emlet DR; Brown KA; Kociban DL; Pollice AA; Smith CA; Ong BB; Shackney SE
Mol Cancer Ther; 2007 Oct; 6(10):2664-74. PubMed ID: 17938260
[TBL] [Abstract][Full Text] [Related]
48. Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers.
Yu D
Semin Oncol; 2001 Oct; 28(5 Suppl 16):12-7. PubMed ID: 11706391
[TBL] [Abstract][Full Text] [Related]
49. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer.
Pályi-Krekk Z; Barok M; Isola J; Tammi M; Szöllosi J; Nagy P
Eur J Cancer; 2007 Nov; 43(16):2423-33. PubMed ID: 17911008
[TBL] [Abstract][Full Text] [Related]
50. [Enhancement of HER-2 degradation by carbamazepine in breast cancer SKBR-3 cell line].
Meng QW; Zhao CH; Xi YH; Cai L; Sun LC; Sui GJ
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):503-6. PubMed ID: 17147113
[TBL] [Abstract][Full Text] [Related]
51. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.
Zhang Y; Zhang J; Liu C; Du S; Feng L; Luan X; Zhang Y; Shi Y; Wang T; Wu Y; Cheng W; Meng S; Li M; Liu H
Cancer Lett; 2016 Nov; 382(2):176-185. PubMed ID: 27597738
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
[TBL] [Abstract][Full Text] [Related]
53. Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way.
Lerdrup M; Hommelgaard AM; Grandal M; van Deurs B
J Cell Sci; 2006 Jan; 119(Pt 1):85-95. PubMed ID: 16352662
[TBL] [Abstract][Full Text] [Related]
54. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
Warburton C; Dragowska WH; Gelmon K; Chia S; Yan H; Masin D; Denyssevych T; Wallis AE; Bally MB
Clin Cancer Res; 2004 Apr; 10(7):2512-24. PubMed ID: 15073131
[TBL] [Abstract][Full Text] [Related]
55. Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel.
Bria E; Furlanetto J; Carbognin L; Brunelli M; Caliolo C; Nortilli R; Massari F; Pedron S; Manfrin E; Pellini F; Bonetti F; Sperduti I; Pollini GP; Scarpa A; Tortora G
Clin Breast Cancer; 2015 Feb; 15(1):16-23. PubMed ID: 25034441
[TBL] [Abstract][Full Text] [Related]
56. The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments.
Cortese K; Howes MT; Lundmark R; Tagliatti E; Bagnato P; Petrelli A; Bono M; McMahon HT; Parton RG; Tacchetti C
Mol Biol Cell; 2013 Jan; 24(2):129-44. PubMed ID: 23154999
[TBL] [Abstract][Full Text] [Related]
57. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells.
Lu Y; Zi X; Zhao Y; Pollak M
Biochem Biophys Res Commun; 2004 Jan; 313(3):709-15. PubMed ID: 14697248
[TBL] [Abstract][Full Text] [Related]
58. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
Seoane S; Montero JC; Ocaña A; Pandiella A
J Natl Cancer Inst; 2010 Sep; 102(18):1432-46. PubMed ID: 20811002
[TBL] [Abstract][Full Text] [Related]
59. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
60. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity.
Pegram MD; Slamon DJ
Semin Oncol; 1999 Aug; 26(4 Suppl 12):89-95. PubMed ID: 10482199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]